Edit

Knopp Biosciences LLC

https://www.knoppbio.com/

Last activity: 13.07.2022

Active

Categories: BioTechDevelopmentDrugHealthTechLifeMediaMedTechSocial

Knopp Biosciences seeks to discover, develop, and deliver breakthrough medicines for urgent unmet medical needs. Our goal is to accelerate and advance treatment, change the course of devastating diseases, and improve the lives of patients and their families.

Check out our other social media profiles!
Facebook: https://www.facebook.com/knoppbio/
Twitter: https://twitter.com/KnoppBio

Followers

693

Mentions

Location: United States, Pennsylvania, Pittsburgh

Employees: 11-50

Total raised: $19M

Twitter

Facebook

Investors 2

Date	Name	Website
-	Innovation...	innovation...
-	LaunchCyte	launchcyte...

Funding Rounds 2

Date	Series	Amount	Investors
12.11.2020	Series C	$14M	-
11.12.2014	-	$5M	-

Mentions in press and media 18

Date	Title	Description
13.07.2022	Areteia Therapeutics Raises $350M To Create An Oral Asthma Treatment	2 Shares Email Facebook Twitter LinkedIn The first oral drug for eosinophilic asthma patients may be on the horizon. Asthma-focused Areteia Therapeutics launched this week with $350 million in Series A funding led by Bain Capital Life Scien...
19.02.2021	Knopp Biosciences Launches New Website with Digital Silk Showcasing Innovative Medical Science and Drug Development	Knopp Biosciences website by Digital Silk NEW YORK (PRWEB) February 19, 2021 Digital Silk, a creative digital agency, has launched a sleek, new website for Knopp Biosciences, US-based drug discovery and development company focused on delive...
12.11.2020	Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers
12.11.2020	Knopp Biosciences Raises $14M Series C Financing	Knopp Biosciences, a Pittshburgh, PA-based drug discovery and development company, completed a Series C equity financing of approximately $14m. The round was led by Solas BioVentures, whose managing director, C. David Adair, M.D., was elect...
12.11.2020	Knopp Biosciences Completes Approx. $14M Series C Financing	Knopp Biosciences, a Pittshburgh, PA-based drug discovery and development company, completed a Series C equity financing of approximately $14m. The round was led by Solas BioVentures, whose managing director, C. David Adair, M.D., was elect...
12.11.2020	Knopp Biosciences Raises $14M Series C Financing	Knopp Biosciences, a Pittshburgh, PA-based drug discovery and development company, completed a Series C equity financing of approximately $14m. The round was led by Solas BioVentures, whose managing director, C. David Adair, M.D., was elect...
25.03.2017	Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers	Knopp Biosciences announced the appointment of Shane Kovacs to its Board of Managers. Kovacs joins the board as the the company initiates advanced clinical development of dexpramipexole in hypereosinophilic syndrome (HES) and eosinophilic a...
07.03.2017	Knopp Biosciences Announces Publication of Eosinophil-lowering Effects of Dexpramipexole in Multiple Clinical Trials	Knopp Biosciences LLC announced the publication of results from multiple clinical trials demonstrating the eosinophil-lowering effects of dexpramipexole, a small molecule treatment in development for eosinophil-associated diseases.
27.01.2017	Knopp Biosciences Receives Key Patent Directed to Ion Channel Activators for Brain Disorders	Knopp Biosciences LLC announced it has received the patent entitled “Benzoimidazol-1,2-yl amides as Kv7 channel activators” The patent strengthens the company’s efforts directed to a series of orally available small molecules for treatment ...
05.01.2017	Knopp Biosciences Receives Key Patent Directed to Treatment for Hypereosinophilic Syndromes, Asthma, and Other Eosinophilic Diseases	Knopp Biosciences LLC announced it received U.S. Patent No. 9,468,630 entitled “Compositions and Methods for Treating Conditions Related to Increased Eosinophils”. The patent relates to the company’s clinical-stage small molecule dexpramipe...
14.12.2016	Knopp Biosciences Reported Steroid-sparing Effects of Dexpramipexole in HES at American Society of Hematology 2016 Annual Meeting	Knopp Biosciences LLC today announced the presentation of data from an ongoing, open-label pilot-study of dexpramipexole in hypereosinophilic syndromes (HES) demonstrating hematological responses, symptom improvement, and steroid sparing in...
29.04.2015	Biogen CEO rehashes old ALS clinical trial: “It was the single-most negative trial I’ve ever seen.”	The trial had generated an immense amount of hope among the ALS community – so the failure was particularly devastating, Scangos said. He’s been very transparent about the trial’s failure, having actually written a Bloomberg editorial at th...
15.12.2014	Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication	A lot of hopes were pinned on using dexpramipexole to treat those with ALS. But it the small molecule drug, thought to maintain mitochondrial function, flopped in Biogen Idecs Phase 3 trials last year: Though fast-tracked in 2009 for the i...
11.12.2014	Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication	Here’s Knopp’s pipeline: The NIH’s National Institute of Allergy and Infectious Diseases is working with Knopp to conduct a clinical trial of dexpramipexole in hypereosinophilic syndrome, or HES, which causes multiple organ damage. Dexprami...
18.03.2014	Knopp Biosciences Broadens Collaboration with NIH to Investigate Eosinophil-Lowering Effects of Dexpramipexole	PITTSBURGH Knopp Biosciences LLC today announced a second collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to investigate the eosinophil-lowering effect...
09.01.2014	Knopp Biosciences and NIH to Collaborate in Evaluating Dexpramipexole in Patients with Hypereosinophilic Syndrome	PITTSBURGH Knopp Biosciences LLC today announced a collaboration agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to conduct a clinical trial of dexpramipex...
-	Biogen CEO rehashes old ALS clinical trial: “It was the single-most negative trial I’ve ever seen.”	Biogen‘s made headlines of late for committing $2.5 billion on a Alzheimer’s drug development gamble – and, notably, preparing for a return to the ALS market. Making such broad commitments can stir a lot of hope up among a desperate patient...
-	Knopp Biosciences raises $5M, pivots flailing ALS drug to target new indication	A lot of hopes were pinned on using dexpramipexole to treat those with ALS. But it the small molecule drug, thought to maintain mitochondrial function, flopped in Biogen Idec’s Phase 3 trials last year: Though fast-tracked in 2009 for the i...

Knopp Biosciences LLC

Investors 2

Funding Rounds 2

Mentions in press and media 18

Reviews 0